{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:05:14Z","timestamp":1768014314062,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pupt.2020.101965","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:53:44Z","timestamp":1602204824000},"page":"101965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps"],"prefix":"10.1016","volume":"64","author":[{"given":"Osamu","family":"Matsuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seijiro","family":"Minamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2020.101965_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000128659","article-title":"Asthma and sinusitis: association and implication","volume":"147","author":"Matsuno","year":"2008","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.pupt.2020.101965_bib2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2020.101965_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaip.2019.08.007","article-title":"Asthma is the dominant factor for recurrence in chronic rhinosinusitis","volume":"8","author":"Sella","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2020.101965_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.03.034","article-title":"Clinical predictors of remission and persistence of adult-onset asthma","volume":"141","author":"Westerhof","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2020.101965_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/biom10020326","article-title":"Reduced local response to corticosteroids in eosinophilic chronic rhinosinusitis with asthma","volume":"10","author":"Kobayashi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.pupt.2020.101965_bib6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk factors of frequent exacerbations in difficult-to-treat asthma","volume":"26","author":"ten Brinke","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2020.101965_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127228","article-title":"Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the United Airways Concept Further Supported","volume":"10","author":"H\u00e5kansson","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pupt.2020.101965_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagas","year":"2020","journal-title":"Allergol. Int."},{"key":"10.1016\/j.pupt.2020.101965_bib9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2020.101965_bib10","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"CALIMA study investigators, Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2020.101965_bib11","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"SIROCCO study investigators, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2020.101965_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"BORA study investigators, Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2020.101965_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2020.101965_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"National heart, lung, blood institute's severe asthma research program","volume":"119","author":"Moor","year":"2007","journal-title":"J. Allery Clin. Immunol."},{"key":"10.1016\/j.pupt.2020.101965_bib15","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/all.12222","article-title":"Chronic rhinosinusitis in asthma is a negative predictor of quality of life: results from the Swedish GA(2)LEN survey","volume":"68","author":"Ek","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2020.101965_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/194589240201600301","article-title":"Eosinophilia in the ethmoid mucosa and its relationship to the severity of inflammation in chronic rhinosinusitis","volume":"16","author":"Szucs","year":"2002","journal-title":"Am. J. Rhinol."},{"key":"10.1016\/j.pupt.2020.101965_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2500\/ajra.2011.25.3613","article-title":"Association between severity of asthma and degree of chronic rhinosinusitis","volume":"25","author":"Lin","year":"2011","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.pupt.2020.101965_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.anai.2016.09.439","article-title":"Association of severity of chronic rhinosinusitis with degree of comorbid asthma control","volume":"117","author":"Phillips","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2020.101965_bib19","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.pupt.2019.101830","article-title":"Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose","volume":"58","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2020.101965_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/all.14178","article-title":"Postbronchodilator lung function improvements with benralizumab for patients with severe asthma","volume":"75","author":"Mathur","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2020.101965_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Hawarth","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2020.101965_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40413-016-0112-5","article-title":"Eosinophilic bioactivities in severe asthma","volume":"9","author":"Carr","year":"2016","journal-title":"World Allergy Organ. J."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:42Z","timestamp":1761082242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553920301693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"alternative-id":["S1094553920301693"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101965","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101965"}}